ERBB3 and breast cancer: Our data showed that inactivation of erbB3 signaling with MM-121 specifically downregulated Survivin in our in vitro models, and significantly enhanced paclitaxel-induced cytotoxicity and apoptosis in the otherwise resistant breast cancer cells (Figures 1 and 2).